Citi On The Impact Of Biosimilars And Losing $360 Billion In Revenues

By: via Benzinga
Citi analyst Andrew Baum released research notes on several pharmaceutical companies Monday. Baum’s overarching theme was about ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.